The JUPITER Trial
Top Cited Papers
- 1 May 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 2 (3) , 279-285
- https://doi.org/10.1161/circoutcomes.109.868299
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Tracking of High-Sensitivity C-Reactive Protein after an Initially Elevated Concentration: The JUPITER StudyClinical Chemistry, 2009
- National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular DiseaseClinical Chemistry, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor TrialCirculation, 2006
- The immune response in atherosclerosis: a double-edged swordNature Reviews Immunology, 2006
- Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/lJournal of the American College of Cardiology, 2005
- Statins and Blood CoagulationArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular EventsNew England Journal of Medicine, 2002
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenNew England Journal of Medicine, 1997